Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia

32% of Patients Achieved Treatment-Free Remission for at Least Six Months in a Single-Arm Trial 93% of Patients Achieved a Platelet Response THOUSAND OAKS, Calif., Oct. 18, 2019 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) today ... Biopharmaceuticals, FDA Amgen, Nplate, romiplostim, Immune Thrombocytopenia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news